Olive Lifesciences, a leading manufacturer of botanical extracts, collaborated with Victoria University (Melbourne, Australia) for evaluating appetite suppressant properties associated with Coleus forskohlii in overweight and obese individuals of Australian population. Victoria University is the Primary sponsor of the study.
“The clinical study will be a lead from the recently published animal data showing positive effect of coleus on appetite suppressant property. It has been suggested that forskolin, an active molecule of coleus may also suppress appetite thus reduce energy intake and results in weight loss. In addition to the appetite suppressant properties of Coleus forskohlii extract, the effect on central obesity and risk factors of metabolic syndrome will also be investigated,” said Dr. Shiv, co-investigator of the study and vice president of Olive Lifesciences.
A randomized, double blind, placebo-controlled study is designed for 12 weeks and began enrolling the subjects. Changes in appetite will be assessed using visual analogue scale; blood hormone levels will also be measured along with lipid profile. The clinical study is registered in Australian New Zealand Clinical Trials Registry (ANZCTR) and is available for public access. ANZCTR has been established at the NHMRC Clinical Trials Centre, University of Sydney, with funding from the Australian National Health and Medical Research Council (NHMRC) and New Zealand Health Research Council.
“We are continually strengthening the research portfolio of our ingredient offerings, as well as identifying efficacious new compounds to help manage health conditions of concern to our customers,” said Mr. Anzar, MD, Olive Lifesciences. “Victoria University is renowned for its pioneering discoveries in biological research, and we are pleased to have entered into this research partnership with the organization.”